The design of effective nonviral gene transfer protocols for primary human hematopoietic cells, including CD34 + hematopoietic progenitor cells (HPC) and T lymphocytes, is a challenging approach towards gene therapy of cancer and infectious diseases such as the acquired immunodeficiency syndrome (AIDS). [1] [2] [3] To date, gene transfer in primary human HPC and T cells has mainly focused on retroviral vectors based on a replication-incompetent Moloney murine leukemia virus (MuLV).
4,5 However, MuLV-based vectors do not efficiently transduce unstimulated human HPC as they require dividing cells for effective transduction. 6 Therefore, nonviral vectors are being explored as alternative strategies to achieve short-term 7 and long-term 8 transgene expression in HPC. Although cationic lipids have been shown to be effective as nonviral vectors in vitro and in vivo, 9 limited success has been obtained in liposome-mediated transfection of HPC or primary cultures of lymphocytes. 10, 11 This illustrates the need and potential utility of an alternative and efficient nonviral protocol for transient gene expression in HPC and primary T cells. Electroporation stimulation. Kinetic analysis of EGFP expression revealed that activated T lymphocytes maintained transgene expression at high levels for a prolonged period. In addition, fresh unstimulated BM CD34
+ cells were consistently transfected (5.2 ± 0.4%) with minimal cytotoxicity (Ͻ5%), even without preliminary CD34
+ cell purification. Both T cells and CD34
+ cells retained their phenotype and functional capacity after electroporation. These results demonstrate that electroporation is a suitable nonviral transfection technique that may serve applications in gene therapy protocols using T lymphocytes or CD34 + cells. Gene Therapy (2000) 7, 1431-1437.
is a standard technique for nonviral transfection of both primary and transformed human hematopoietic cells, 12, 13 and has potential for gene therapy applications ex vivo 14 and in vivo. 15 As it is a physical transfection method, gene transfer does not require cell-type-specific receptors, unlike viral vectors. In addition, electroporation is highly reproducible, time-saving and cost-effective. Recently, we have demonstrated efficient transient transfection by electroporation in primary CD34
+ progenitor-derived dendritic cells (DC) and Langerhans cells (LC). 16 Here, we want to extend our electroporation protocol to transfect HPC and primary T lymphocytes. Recently, Satoh et al 17 demonstrated that peripheral blood CD34 + HPC could be transfected by electroporation by EBV-based vectors. Also, Ebert et al 18 demonstrated that electroporation of lymphocytes, unlike lipofection and receptormediated transfection, induced no significant TNF␣ production correlated with induction of apoptosis. However, very little data on cell viability and transfection efficiency were provided due to the use of enzymatic bulk assays or PCR analysis to detect reporter gene expression. Here, we want to explore the efficiency of transfection by electroporation in primary human CD34
+ cells and T lymphocytes using a plasmid vector encoding the enhanced green fluorescent protein gene (EGFP). This EGFP reporter system allowed optimization of the electroporation procedure towards efficiency, viability and trans-gene expression on a single-cell level by flow cytometric (FCM) analysis. 19 In the process of optimizing transient electroporation of hematopoietic cells, voltage and capacitance were found to be the most critical parameters since increasing voltages result in increased numbers and size of pores, while capacitance is linearly correlated with pulse time (according to the equation = R × C, where is pulse time, R resistance and C capacitance) which determines the duration of the pore-formation. 20 In preliminary experiments using leukemic cell lines, we observed that leukemic cells could be successfully transfected at lower voltage pulses (200-300 V) in combination with a relatively high capacitance (1050-1500 F), which is in accordance with a previous report. 21 Electroporation efficiency in leukemic cell lines (Jurkat, Sup-T1, Molt-3, HSB-2, K562, KG-1, U-937 and HL-60, all obtained from the American Type Culture Collection (ATCC), Rockville, MD, USA) was in the range of 28-52%. Decreasing the volume in the electroporation cuvette or further increasing capacitance to for example 3000 F led only to longer pulse times and excessive cell death (data not shown). At increasing voltages the percentage of transfected cells within the viable population increased but overall efficiency at higher voltages decreased as cell survival became a limiting factor. By balancing survival rate and electroporation efficiency -in terms of absolute numbers of viable EGFP + cells -optimal parameters were determined for primary human T lymphocytes. Peripheral blood lymphocytes (PBL) were prestimulated with PHA for 2 days and electroporated at various settings. We established that electroporation at 300 V (and 1050 F) was optimal for electroporation of activated T lymphocytes. Absolute transient efficiency in 2-day prestimulated T lymphocytes peaked at 16% and cell mortality at these electrical settings was 70% (Figure 1 ). Due to this initial toxic effect, further culture of T cells electroporated at 300 V in the presence of IL-2 for 1 week resulted in a somewhat lower expansion (eight-to 10-fold) as compared with non-electroporated T cells (12-to 15-fold) . Several attempts to electroporate unstimulated T cells resulted in undetectable EGFP expression, which emphasizes the need for a mitogenic stimulus before transfection of T cells. 22 Moreover, transfection of activated T cells by DMRIE-C-mediated lipofection did not result in detectable EGFP expression.
In order to investigate the effect of prestimulation time on transfection efficiency, peripheral blood lymphocytes (PBL) were stimulated with PHA for 1 to 3 days (Ͼ95% of cells bore T cell markers after prestimulation) and subsequently transfected by electroporation at optimal parameters. We obtained high-efficiency gene transfer by electroporation in 1-to 3-day PHA-stimulated CD2 + T cells. A representative dot plot of EGFP-transfected 1-day PHA-prestimulated T cells is shown in Figure 2a , confirming the presence of CD2 + EGFP + T cells (± 12%). Maximum transfection levels were observed after a 2-day prestimulation (Figure 2b ). FCM analysis revealed 16.3 ± 1.3% EGFP + cells 24 h after electroporation, which was significantly higher than 1-day (9.6 ± 2.9%) and 3-day (10.5 ± 1.9%) stimulated T cells.
As the use of PHA should be avoided in clinical trials, we also investigated electroporation efficiency of anti-CD3/IL-2-stimulated PBL. Substitution of PHA activation by CD3 cross-linking followed by IL-2 stimulation 
Figure 1 Optimization of electroporation in primary T cells. Peripheral blood was obtained from hemachromatosis patients after informed consent and peripheral blood mononuclear cells (PBMC) were isolated by density gradient centrifugation using Lymphocyte Separation Medium (ICN Biomedicals, Costa Mesa, CA, USA). PBMC were resuspended in AIM-V medium (Gibco BRL, Paisley, UK) and allowed to attach to plastic dishes in order to remove monocytes. After 2 h at 37°C, the non-adherent cell fraction was used as peripheral blood lymphocytes (PBL). Non-adherent PBMC were grown in AIM-V (Gibco

cell fraction (normal lines) were set using control-transfected T lymphocytes as background controls (bold lines). Note the vast increase of the percentage of EGFP-expressing cells accompanied by a decrease of the mean fluorescence intensity in the EGFP
+ population over time.
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Electroporation of primary T cells and CD34
+ cells VFI Van Tendeloo et al resulted in a significantly lower transfection efficiency in 1-day (5.3 ± 2% with anti-CD3/IL-2 versus 9.6 ± 2.9% with PHA, P Ͻ 0.05) and 2-day (8.9 ± 2.5% with anti-CD3/IL-2 versus 16.3 ± 1.3% with PHA, P Ͻ 0.01) prestimulated T cells, but we observed a slight but significant increase in efficiency in 3-day anti-CD3/IL-2-stimulated as compared with 3-day PHA-activated T cells (13.5 ± 1.3% versus 10.5 ± 1.9%, respectively, P Ͻ 0.05), as depicted in Figure 2b .
In order to verify that electroporation had no adverse effects on the function of T cells, we electroporated an IL-2-dependent CD8
+ tumor infiltrating lymphocyte (TIL) 1235 clone recognizing the HLA-A2-restricted Melan [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] epitope. 23 Following electroporation of the TIL clone at 300 V and 1050 F, we detected 9 ± 3.5% EGFP + TIL. Electroporated TIL responded as vigorously by IFN-␥ release to Melan-A 25-37 peptide-pulsed HLA-A2 + T2 cells (kindly provided by Pierre Van der Bruggen, Ludwig Institute for Cancer Research, Brussels Branch), as control non-electroporated TIL, also exposed to the same targets (25.6 ± 4 versus 28 ± 3.5 IU/ml IFN-␥, respectively, n = 3). These results show that electroporation does not adversely affect T cell function and suggest that our electroporation protocol might serve applications in adoptive immunotherapy strategies in which T cells are genetically modified with immune-enhancing cytokines modulating anti-tumor immune responses. 24 This also suggests the possibility of establishing stable transfectants of primary T cells or T cell clones by consecutive EGFP-based fluorescence-activated cell sorting (FACS), since T cells can be cultured and expanded in vitro for months allowing integration of the electroporated plasmid, selection of stable transfectants by FACS and subsequent expansion. 25 Using a FACStar PLUS cell sorter, we routinely obtained between 2 and 5 × 10 5 CD34 + cells starting from 8 to 12 ml of a fresh adult bone marrow sample. FCM analysis showed purities Ͼ98% CD34 positivity on the day of isolation (data not shown). CD34
+ cells undergo substantial proliferation and differentiation to committed myeloid progenitors, precursors and differentiated cells when maintained in serum-or cytokine-containing medium. 26 This differentiation is paralleled by a loss of CD34 expression. During culture in medium supplemented with IL-3+IL-6+SCF, CD34
+ cells underwent substantial proliferation (four-fold and 15-fold expansion by days 4 and 7, respectively). Here, we evaluated electroporation as an alternative for transfection of both freshly isolated and 1-to 4-day cultured CD34 + cells. The EGFP reporter system in combination with FCM analysis allowed accurate determination of transfection efficiency in combination with simultaneous CD34 antigen staining at a single-cell level. Optimization of the electroporation procedure was performed on 2-day cultured CD34 + cells, using the same approach as described for electroporation of T lymphocytes. Highest absolute numbers of viable EGFP + CD34 + cells were obtained when electroporation was performed at 260 V with a capacitance of 1050 F (data not shown). As Flt-3 ligand (FL) has been reported to be an early-acting growth factor for HPC, 27 we first investigated the effect of the presence of FL during CD34 + cell culture on transfection efficiency. As the presence of FL during culture significantly increased electroporation efficiency (21.7 ± 1.5% without FL versus 28.5 ± 2.1% with FL; P Ͻ 0.01), FL was routinely added to all further cultures. Kinetic analysis of EGFP expression in CD34 + cells transfected after 2 days of culture in IL3+IL-6+SCF+FL revealed peak expression from 24 to 48 h after electroporation. Four days after gene delivery, 50% of the peak expression was still present in the cells. Subsequently, there was a steady decline to background levels 1 week after transfection (Figure 3) . Figure 4a shows a representative FACS profile of 2-day stimulated CD34
+ cells. Table  1 shows the outcome of electroporation of cultured CD34
+ cells at different time-points in more detail. Transfection of 2-day cultured CD34
+ cells was most optimal with regard to efficiency (29.6 ± 4.7% at day 2 versus 11.3 ± 1.0% at day 1; P Ͻ 0.001) despite the significant lower survival rate compared with 1-day-stimulated CD34 +
cells. Although transfection efficiency, in terms of percentage of viable EGFP
+ cells, after 4 days was not significantly lower than at day 2, the levels of CD34 expression favored the use of 2-day stimulated CD34 + cells (Table 1) .
A recent report on nonviral transfection of CD34 + cells by a gene gun technique demonstrated successful transfection of cord blood CD34
+ cells and mentioned a transfection efficiency of approximately 6% in LacZ-transfected 4-day cultured CD34 + cells, 7 which is substantially lower than the transfection efficiency obtained by our protocol (26%), using the same culture conditions. Nevertheless, their optimal time-point of transfection (upon day 2 of culture), as well as the CMV-driven luciferase expression kinetics, were in concordance with our observations.
Strikingly, electroporation of unstimulated, fresh 
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Figure 4 FACS profiles of fresh and cultured EGFP-transfected CD34
ϩ cells. CD34 ϩ cells were sorted from total bone marrow mononuclear cells and electroporated as described in Table 1 
CD34
+ cells resulted in a marked EGFP expression in approximately 5% of the CD34 + cells (depicted in Figure  4b ). Interestingly, electroporation of fresh CD34 + cells was accompanied by only a minimal mortality (less than 5%) in contrast to a classical 20-50% mortality rate in other cell types. Phenotypic analysis revealed that 95% of the cells were still CD34 + 24 h after electroporation. We also investigated whether electroporated CD34 + cells were still functional in terms of their colony-forming capacity in vitro. Using a colony-forming unit (CFU)-assay in methylcellulose semi-solid medium, we observed no significant difference between the colonyforming capacity of electroporated versus non-electroporGene Therapy
ated CD34
+ cells (147 ± 40 versus 134 ± 30 CFC, respectively, n = 4).
As the CD34 + cell fraction comprises only 1-5% of adult BM mononuclear cells (BMMC), we also investigated the efficiency of transfection by electroporation of total BMMC. While an overall transfection efficiency of nearly 2% was observed (data not shown), Figure 4c clearly demonstrates that transient electroporation efficiency within the CD34 + compartment is similar to that obtained with purified CD34
+ cells (5% EGFP + cells). These results clearly highlight electroporation as a valid and effective nonviral method for gene delivery into both fresh and cultured CD34
+ cells, even without preliminary 29.6 ± 4.7 78.0 ± 3.4 66 day 4 (n = 5)
26.3 ± 3.9 74.7 ± 4.9 45
Adult bone marrow (BM) samples were collected after informed consent by sternal aspiration from hematologically normal patients undergoing cardiac surgery. Mononuclear BM cells were isolated from adult BM by density gradient centrifugation using Lymphocyte Separation Medium and stained with supernatant of the 43A1 hybridoma (anti-CD34, kindly donated by Dr H-J Bü hring, University of Tü bingen, Germany), 33 followed by fluorescein isothiocyanate (FITC)-conjugated rabbit anti-mouse immunoglobulins (DAKO, Glostrup, Denmark). The CD34-labeled cells were then sorted on a FACStar PLUS cell sorter (Becton Dickinson, Erembodegem, Belgium) as described elsewhere. 34 Sort windows were set to include cells with low side scatter and with positive green fluorescence (CD34 + ). Purities of Ͼ98% were routinely obtained. Sorted CD34 + cells were plated at 10 5 cells/ml in 2 ml IMDM supplemented with 1% bovine serum albumin (BSA; Sigma, Bornem, Belgium), 100 ng/ml interleukin (IL)-3 (kindly provided by Dr SC Clark, Genetics Institute, Cambridge, MA, USA), 100 ng/ml IL-6 (Roche Molecular Biochemicals, Mannheim, Germany), 50 ng/ml stem cell factor (SCF) (Biosource, Nivelle, Belgium) and 100 ng/ml Flt-3 ligand (FL) (kindly provided by Dr SC Lyman, Immunex Corporation, Seattle, WA, USA).
At different time-points after initiation of the cell culture with IL-3+IL-6+SCF+FL, fresh or cultured CD34 + cells were resuspended at 2 × 10 6 cells/ml and 500 l of cell suspension was mixed with 20 g of pEGFP-N1 (Clontech Laboratories, Palo Alto, CA, USA) containing an enhanced green fluorescent protein (EGFP) reporter gene, incubated for 1 min at room temperature and electroporated with an Easyject Plus apparatus (EquiBio, Kent, UK) at optimized parameters (260 V, 1050 F). One day after electroporation, transfected CD34
+ cells were washed once in PBS supplemented with 1% FCS and resuspended in 0.5 ml of PBS supplemented with 1% BSA and 0.1% azide. Ethidium bromide (EB) at a final concentration of 10 g/ml was added directly before FCM analysis. Electroporation efficiency is expressed as the mean percentage of EGFP + cells 24 h after electroporation. Viability was determined by FCM analysis of ethidium bromide exclusion and is expressed as the percentage of ethidium bromide-negative cells. Data are shown as mean ± s.d. The level of CD34 expression was determined simultaneously with EGFP fluorescence 24 h after transfection at the indicated time-point by immunophenotypic analysis, as described previously. 16 Briefly, 5 × 10 5 transfected cells were washed once in PBS supplemented with 1% FCS and stained for 30 min at 4°C with 1 g of monoclonal antibody in 150 l of PBS containing 1% BSA and 0.1% azide and analyzed on a FACScan flow cytometer. In order to allow combination with EGFP analysis, a phycoerythrin (PE)-conjugated monoclonal CD34 antibody (Becton Dickinson) was used. To set quadrants, a nonreactive isotype-matched monoclonal antibody (Becton Dickinson) was used (see also Figure 4 ) and is expressed as the mean of three independent experiments.
CD34
+ cell sorting. Together, our results show that electroporation can markedly transfect not only cultured CD34 + HPC at different stages but also unstimulated, freshly isolated CD34 + cells. These observations confirm that electroporation is able to transfect primary unstimulated CD34
+ cells, unlike retroviral MuLV-based vectors. 28 Interestingly, we observed a similar transfection efficiency within the CD34 + compartment of the total BMMC fraction as compared with that of highly purified CD34 + cells. Aside from saving time and being cost-effective, this feature could be of importance for future applications of this electroporation-based protocol, as it might eliminate the need for preliminary cell selection procedures, such as FACsorting. The current electroporation technique may thus provide a highly effective and rapid means to transfect CD34 + cells with no or minimal prestimulation, thereby avoiding prolonged ex vivo cultivation and/or exposure to differentiation-promoting cytokines, which might be detrimental for ex vivo gene transfer applications using primitive hematopoietic stem cells, present within the CD34 + population. 29 However, it remains to be determined whether hematopoietic stem cells were included in the transfected CD34 + population. Taken together, electroporation of HPC or T cells may be more beneficial in some gene therapy settings, such as transient expression of bone marrow-protecting genes (eg MDR, cytokines); 30 short-term expression of cytokines and/or growth factors; 31 oncogene antisense oligonucleotides in bone marrow purging settings; 32 or transient expression of viral receptor genes in combination with viral transduction protocols. 7 We conclude that electroporation represents a valuable nonviral transfection tool for high-level short-term expression of transgenes in both human CD34
+ HPC and primary activated T lymphocytes and may ultimately find clinical applications in BM transplantation and/or gene therapy protocols that might benefit from shortterm expression of therapeutic gene products in T lymphocytes and CD34 + cells.
